Rhode Island Reintroduces Expanded Kratom Bill as Missouri AG Widens Probe to 22 Entities

TL;DR

Rhode Island lawmakers reintroduced a substantially expanded kratom regulation bill, growing the measure from six pages to 25 with input from the state health department. Missouri's attorney general expanded her kratom investigation to 22 entities across the supply chain, and California's AB 1088 continued advancing age restrictions and labeling requirements for kratom and 7-OH products.

Rhode Island reintroduces expanded kratom regulation bill

Rhode Island lawmakers reintroduced a kratom regulation bill that has grown substantially since its last iteration, expanding from six pages to 25, according to News From the States. The sponsors said the revised bill was crafted with input from the state health department after last year's version was vetoed.

Sen. Pamela Lauria Kennedy told reporters she would prefer to keep the health department's suggested language intact. The bill reportedly leaves "kratom cocktails" for future legislation, focusing the current measure on product regulation.

Reviews of the expanded proposal are mixed, according to the report. The bill's growth from six to 25 pages reflects a broader pattern across state legislatures, where initial kratom proposals are giving way to more detailed regulatory frameworks as the policy landscape matures.

Missouri attorney general widens kratom investigation

Missouri Attorney General Catherine Hanaway announced that her office is expanding a statewide kratom investigation to 10 additional entities across the supply chain, bringing the total number of companies under investigation to 22.

Hanaway's office had already filed suit against CBD American Shaman and related entities over kratom and alkaloid sales. The expanded probe targets upstream suppliers and distributors, a shift from the initial focus on retail-facing companies.

The Missouri investigation is one of the most aggressive state-level enforcement actions currently underway. The probe follows a pattern seen in several states where attorneys general have moved on kratom restrictions through enforcement channels rather than waiting for legislative action.

California's AB 1088 advances as state enforcement continues

In California, Assemblymember Jasmeet Bains' AB 1088 continued advancing through the legislature, according to CalMatters. The bill would place kratom and 7-hydroxymitragynine (7-OH) under the state's food and drug law, require warning labels and child-resistant packaging, and ban sales to people under 21.

At a recent Senate health hearing, state officials told lawmakers they consider kratom and 7-OH products unlawful under current policy and described ongoing enforcement actions against manufacturers, wholesalers, and retailers.

California's enforcement effort has shown measurable results. Governor Gavin Newsom announced in March that businesses were 95% compliant in removing 3,308 illegal kratom and 7-OH products from shelves, based on more than 1,839 licensee visits. AB 1088 would formalize the enforcement framework in statute.

The California approach contrasts with Washington State, where a House committee heard a bill sponsored by Rep. Kristine Reeves to create a regulatory framework with preemption measures, reflecting a regulatory model rather than a prohibitory one.

Postharvest handling shown to shift kratom alkaloid levels

A study published in Frontiers in Plant Science reported that postharvest handling of kratom leaf can substantially change alkaloid composition. The researchers found that withering generally increased mitragynine concentrations, with especially notable effects in certain cultivars.

The study reported that 12 hours of withering followed by drying below 40 degrees Celsius increased speciogynine and paynantheine concentrations. The researchers concluded that genotype, season, and postharvest handling all influence kratom alkaloid composition and concentration.

The research arrives as the FDA continues to push for scheduling of concentrated 7-OH products while distinguishing them from natural kratom leaf. Data on how routine processing shifts alkaloid profiles feeds directly into ongoing regulatory questions about what constitutes "natural" versus "concentrated" alkaloid levels, a distinction that the bipartisan Senate letter urging the FDA to schedule whole kratom leaf has made central to the federal policy debate.

Sources

Sources